News

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.

The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York City, New York, United States.

A new deep learning model that can identify disease-related features from images of eyes has been unveiled by a group of investigators from Tohoku University.

The lower energy applications and slower sweep speeds offer marked IOP reductions in patients.

Data shows improvement after eye muscle surgery for lower spatial frequencies.

A team of investigators from the Yong Loo Lin School of Medicine at the National University of Singapore has found that there is a bidirectional association between chronic kidney disease and glaucoma.

In a recent study, investigators found preclinical evidence that this innovative, biodegradable microneedle, dip-coated with a therapeutic drug for release upon insertion into the eyeball, can also be equipped with a special hydrogel that simultaneously seals off the insertion hole.

A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.

A team of investigators at Flinders University in Australia have found that a specific cell within the retina appears to be particularly good at housing Ebola and other viruses.

According to investigators, a key reason for the link may lie in circadian “clocks,” the molecular machinery within every cell of every organism, which have evolved to adapt to daily stresses, such as changes in light and temperature caused by the rising and setting of the sun.

Minute movements are related to patching treatment outcomes in patients.

Increasing understanding of the genetics behind Usher syndrome suggests that treatment may become possible in the very near future.

Retina specialists and their patients have learned how AI and telemedicine can be effective in monitoring disease progression and alerting clinicians to early signs of adverse changes.

Biologic treatments can be utilised to help the eye heal itself in inflammatory conditions such as dry eye disorder.

According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular oedema patients.

It is important to select good candidates for presbyopia-correcting IOL implantation and frankly discuss postoperative adjustment issues for a successful outcome.

Each new generation of cyclophotocoagulation options results in more accurate visualisation of the ciliary processes, greater ease of use and fewer complications.

Eye rubbing is an essential factor in the development of keratoconus. “No rub, no cone” is the rule: a genetic predisposition for the disease will come to nothing without excessive eye rubbing.

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

Physicians offer pearls for improving visualisation in eyes using retroillumination techniques.

Practice makes perfect when adopting this method for intrascleral IOL fixation.

An investigator at Anglia Ruskin University is leading work on an anti-cataract drug, which has had positive results in lab tests.

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

Polarisation-sensitive optical coherence tomography has facilitated early diagnosis of disease before it becomes apparent on topography.

Promising gene therapies in development are pinpointing steps in the pathogenic cascades involved in ocular diseases, such as VEGF for wet AMD and CFI for dry AMD.

An ischaemia modulator has demonstrated it is safe and well tolerated in a Phase 1/2a trial in diabetic macular ischaemia patients.

Patients are at risk for developing severe dry eye and ocular surface disease.

With minimally invasive surgery procedures becoming increasingly popular in glaucoma management, canaloplasty using an ab-interno surgical technique offers enhanced natural aqueous outflow in open-angle glaucoma.